Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 8/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 8/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 6/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417549 | 0.88 | NR4A2 (0.56) | NR4A2CREBBPPBRM1HASPIN | |
| SCHEMBL10076716 | 0.84 | NR4A2 (0.56) | NR4A2CREBBPPBRM1HASPIN | |
| SCHEMBL9101649 | 0.83 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL6417553 | 0.82 | NR4A2 (0.51) | NR4A2CREBBPPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL27607023 | 0.82 | NR4A2 (0.51) | NR4A2CREBBPPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL14350625 | 0.80 | NR4A2 (0.51) | NR4A2CREBBPPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL15300951 | 0.79 | NR4A2 (0.61) | NR4A2CREBBPPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5204231 | 0.79 | NR4A2 (0.50) | NR4A2CREBBPPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL5204235 | 0.79 | NR4A2 (0.50) | NR4A2CREBBPPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2493105 | 0.75 | NPC1 (0.64) | NR4A2CREBBPPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507499-B2 | Substituted indole/indazole-pyrimidinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012078674-A1 | SUBSTITUTED INDOLE/INDAZOLE-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142696-A1 | SUBSTITUTED INDOLE/INDAZOLE-PYRIMIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142696-A1 | SUBSTITUTED INDOLE/INDAZOLE-PYRIMIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K20 | NR4A2 2670/4885CREBBP 634/4885PRKAG1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.